paroxinor 20mg potahovaná tableta
orion corporation, espoo array - 15320 hemihydrÁt paroxetin-hydrochloridu - potahovaná tableta - 20mg - paroxetin
everolimus sandoz s.r.o. 0,25mg tableta
sandoz s.r.o., praha ČeskÁ republika - 16078 everolimus - tableta - 0,25mg - everolimus
everolimus sandoz s.r.o. 0,75mg tableta
sandoz s.r.o., praha ČeskÁ republika - 16078 everolimus - tableta - 0,75mg - everolimus
aubagio
sanofi winthrop industrie - teriflunomid - roztroušená skleróza - selektivní imunosupresiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
cerdelga
sanofi b.v. - oprávněný - gaucherova choroba - jiné zažívací trakt a produkty metabolismu, - cerdelga je indikován k dlouhodobé léčbě dospělých pacientů s gaucherovou chorobou typu 1 (gd1), kteří jsou pomalí metabolizátoři cyp2d6 (pms), středně rychlým metabolismem (ims) nebo rychlým metabolismem (ems).
teriflunomide mylan
mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).
teriflunomide accord
accord healthcare s.l.u. - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva, selektivní imunosupresiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - antineoplastická činidla - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
aregalu 14mg potahovaná tableta
krka, d.d., novo mesto, novo mesto array - 15618 teriflunomid - potahovaná tableta - 14mg - teriflunomid
boxarid 14mg potahovaná tableta
gedeon richter plc., budapešť array - 15618 teriflunomid - potahovaná tableta - 14mg - teriflunomid